The marketing authorisation (MA) by the EMA for the treatment of M. gallisepticum infections in breeding chickens represent a valuable market expansion opportunity for Aivlosin®. M. gallisepticum (the transmission of which occurs both between birds - which may appear healthy - and from infected breeders to progeny) is a well-known cause of significant losses in commercial poultry operations worldwide. We reiterate our positive stance on ECO as a core holding in the Animal Health sector.
02 Apr 2019
Further market expansion: EMA clears Aivlosin® in breeding chickens
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Further market expansion: EMA clears Aivlosin® in breeding chickens
ECO Animal Health Group plc (EAH:LON) | 85.5 0 0.0% | Mkt Cap: 57.9m
- Published:
02 Apr 2019 -
Author:
Jens Lindqvist -
Pages:
3
The marketing authorisation (MA) by the EMA for the treatment of M. gallisepticum infections in breeding chickens represent a valuable market expansion opportunity for Aivlosin®. M. gallisepticum (the transmission of which occurs both between birds - which may appear healthy - and from infected breeders to progeny) is a well-known cause of significant losses in commercial poultry operations worldwide. We reiterate our positive stance on ECO as a core holding in the Animal Health sector.